CLINICAL TRIALS PROFILE FOR ULTOMIRIS
✉ Email this page to a colleague
All Clinical Trials for ULTOMIRIS
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03920293 ↗ | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | Active, not recruiting | Alexion Pharmaceuticals | Phase 3 | 2019-03-26 | The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG). |
| NCT04248465 ↗ | An Efficacy and Safety Study of Ravulizumab in ALS Participants | Active, not recruiting | Alexion Pharmaceuticals | Phase 3 | 2020-03-30 | The purpose of the study is to assess the efficacy and safety of ravulizumab for the treatment of adult participants with ALS. |
| NCT04390464 ↗ | mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R) | Recruiting | Cambridge University Hospitals NHS Foundation Trust | Phase 4 | 2020-05-08 | TACTIC-R is a randomised, parallel arm, open-label platform trial for investigating potential treatment for COVID-19 disease. While SARS-CoV infection evades detection by the immune system in the first 24 hours of infection, it ultimately produces a massive immune system response in the subgroup of people who develop severe complications. Most tissue damage following infection with COVID19 appears to be due to a later, exaggerated, host immune response. This leads to lung and sometimes multi-organ damage. Most people who develop these severe complications still have virus present in their respiratory tract at the time-point when the disease starts to evolve. Immune modulation in the presence of active infection has potential to cause more harm than benefit. Safety considerations when studying immune modulation strategies are paramount. Therefore, this study proposes to assess the efficacy of immunomodulatory agents that target dysregulated immune response that drive the severe lung, and other organ, damage. The medications investigated for efficacy in this trial are Baricitinib and Ravulizumab. |
| NCT04543591 ↗ | Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant | Recruiting | Alexion Pharmaceuticals | Phase 3 | 2020-09-16 | This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab in adult and adolescent participants with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). In Stage 1, an open-label, single-arm period, the dosing regimen will be confirmed. In Stage 2, participants will be randomized to receive either blinded ravulizumab plus best supportive care or matching placebo plus best supportive care. The treatment period is 26 weeks (open-label for Stage 1, and randomized, double-blind, and placebo-controlled for Stage 2) followed by a 26-week follow-up period. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ULTOMIRIS
Condition Name
Clinical Trial Locations for ULTOMIRIS
Trials by Country
Clinical Trial Progress for ULTOMIRIS
Clinical Trial Phase
Clinical Trial Sponsors for ULTOMIRIS
Sponsor Name
